Lixte Biotechnology Holdings, Inc. (OTCQB: LIXT) Soars 60% After Entering Into Clinical Trial Agreement With Moffitt Cancer Center For Phase 1b/2 Trial of LB-100
Lixte Biotechnology Holdings, Inc. (OTCQB:M LIXT) is a biotech company that focuses on identifying enzyme targets for common serious illnesses ...
